Expertise in
2
conditions

Dr. Geoffrey Gladstein

Rheumatology
Office
5520 Park Ave Ste 101, 
Trumbull, CT 
Expertise in
2
conditions
Office
5520 Park Ave Ste 101, 
Trumbull, CT 

Overview

Geoffrey Gladstein is a Rheumatologist in Trumbull, Connecticut. Dr. Gladstein is highly rated in 2 conditions, according to our data. His top areas of expertise are Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Arthritis, and Axial Spondyloarthritis (AxSpA).

His clinical research consists of co-authoring 1 peer reviewed article and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Rheumatology

Licenses

Specialist in CT

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Office
5520 Park Ave Ste 101, Trumbull, CT 06611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

1 Total Publications

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).
Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).
Journal: Annals of the rheumatic diseases
Published: September 16, 2011
Similar Doctors
Expertise in
19
conditions
Dr. Robert F. Spiera
Rheumatology
Expertise in
19
conditions
Dr. Robert F. Spiera
Rheumatology

HSS - Belaire Building

525 East 71st Street, 7th Floor, 
New York, NY 
 (48.9 miles away)
212-860-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Spiera is a Rheumatologist in New York, New York. Dr. Spiera is highly rated in 19 conditions, according to our data. His top areas of expertise are Systemic Sclerosis (SSc), Vasculitis, Rhizomelic Pseudopolyarthritis, and Polymyalgia Rheumatica. Dr. Spiera is currently accepting new patients.

Expertise in
35
conditions
Dr. Alice Gottlieb
Rheumatology
Expertise in
35
conditions
Dr. Alice Gottlieb
Rheumatology

Gramercy Park Physicians LLP

10 Union Sq E, 
New York, NY 
 (51.7 miles away)
212-844-8800
Languages Spoken:
English
See accepted insurances

Alice Gottlieb is a Rheumatologist in New York, New York. Dr. Gottlieb is highly rated in 35 conditions, according to our data. Her top areas of expertise are Psoriasis, Plaque Psoriasis, Generalized Pustular Psoriasis (GPP), and Hidradenitis Suppurativa.

Expertise in
6
conditions
Dr. Monique E. Hinchcliff
Rheumatology
Expertise in
6
conditions
Dr. Monique E. Hinchcliff
Rheumatology

Yale University

6 Devine St, 
North Haven, CT 
 (21.7 miles away)
203-287-6100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Monique Hinchcliff is a Rheumatologist in North Haven, Connecticut. Dr. Hinchcliff is highly rated in 6 conditions, according to our data. Her top areas of expertise are Systemic Sclerosis (SSc), Scleroderma, Raynaud Phenomenon, Scleroma, and Tissue Biopsy.

Frequently Asked Questions about Dr. Geoffrey Gladstein

How do I make an appointment with Dr. Geoffrey Gladstein?

You can book an appointment with Dr. Geoffrey Gladstein by calling their office at 203-371-5873. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Geoffrey Gladstein a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Geoffrey Gladstein is classified as an Advanced expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Geoffrey Gladstein specialize in?

While Dr. Geoffrey Gladstein is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), and Arthritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Geoffrey Gladstein participate in research or clinical trials?

Yes. Dr. Geoffrey Gladstein has published 1 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Dr. Geoffrey Gladstein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Geoffrey Gladstein accept my insurance?

Dr. Geoffrey Gladstein accepts most major insurance plans, including Humana. We recommend calling the office directly at 203-371-5873 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gladstein's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile